Braun AA, Buff J, Moser NH, Sassenburg R, Briel N, Maric A, Schreiner SJ, Jung HH
Phase-targeted auditory stimulation enhances slow-wave activity during sleep in Huntington's disease: A pilot crossover study
J Huntingtons Dis
Nov 01, 2026
15 (4) :641-652
Halabi N, Killoran A, Nopoulos PC
Effect of Vesicular Monoamine Transporter Type-2 Inhibitors on Motor Features in HD
MedRxiv [Preprint]
Sep 28, 2026
Lunven M, Van Den Enden P, Gil Salcedo A, Pertzov Y, Bapst B, Youssov K, Morgado G, Busse M, Massart R, Rosser A, Bachoud-Lévi AC
Visuospatial working memory in Huntington's disease: behavioural and structural brain correlates
J Neurol Neurosurg Psychiatry
Sep 14, 2026
97 (10) :873-881
Jacob SS, Langbehn DR, Stolwyk RJ, Stout JC
The Trail Making Test in healthy controls and Huntington's disease: Demographic effects and normative tables based on a large data set
Psychol Assess
Sep 10, 2026
Gao Y, Ásbjörnsdóttir B, Vinther-Jensen T, Von Essen MR, Hellem MNN, Hjermind LE, Ejlerskov P, Landwehrmeyer GB, Sellebjerg F, Nielsen JE, Lewerenz J
CSF leukocytes transiently increase before onset of Huntington disease in association With a stage-specific CSF cytokine/chemokine pattern
Neurol Neuroimmunol Neuroinflamm
Sep 01, 2026
13 (5) :e200632
Jeyakumar N, Woolnough D, Li G, Teixeira-Pinto A, Jeyakumar V, Loy CT
A novel machine learning approach for the classification of Huntington disease manifestation using motor features
Parkinsonism Relat Disord
Sep 01, 2026
150 :108851
Mclauchlan D, Drew C, Holmans P, Rosser A
Exploring the association between antidepressants, progression and mortality in Huntington's disease
Brain
Aug 03, 2026
149 (8) :2680-2688
Demmin DL, Roché MW, Vaidya JG, Langbehn DR, Fuller RL, Weingast SZ, Sampaio C, Stebbins GT
A clinimetric evaluation of the problem behaviors assessment short form (PBA-s) within the context of the Huntington's disease integrated staging system (HD-ISS)
J Huntingtons Dis
Aug 01, 2026
15 (3) :468-475
Kaddoura A, Dalbro SEJ, van Walsem MR, Pihlstrøm L
Assessing the prognostic value of early oculomotor abnormalities in Huntington's disease
Front Neurol
Jun 15, 2026
17 :1844433
Franch-Marti C, Puig-Davi A, Rodriguez-Antiguedad J, Perez-Perez J, Olmedo-Saura G, Ruiz-Barrio I, Bojtos L, Perez-Carasol L, Tort-Merino A, Pagonabarraga J, Kulisevsky J, Martinez-Horta S
Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease
Brain Commun
Jun 04, 2026
8 (3) :fcag210
Heyd M, Landwehrmeyer GB, Lewerenz J
The pathological Huntingtin CAG triplet expansion differentially affects the diagnosis of systemic and organ-specific autoimmune diseases
Front Immunol
May 08, 2026
17
Vazquez JE, Lin D, Mendizabal A, Ogilvie AC, Stuart EA, Garcia TP
Higher educational attainment in Huntington disease families: evidence from the Enroll-HD study
Orphanet J Rare Dis
Apr 09, 2026
21 (1) :142
Gil-Salcedo A, Massart R, Youssov K, Morgado G, Bachoud-Levi AC
Profiles of patients at early stages of Huntington's disease based on the routine biological markers and the disease progression
J Neurol
Apr 02, 2026
273 (4) :249
Roiboit CM, Langbehn DR, Stout JC
Minimal clinically important difference on cognitive measures for Huntington's disease using function as an anchor
Mov Disord
Apr 01, 2026
41 (4) :870-880
Yao J, Feng G, Shao G, Wang Z, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM
Interplay between sex and cytosine-adenine-guanine-age product score in Huntington's disease: Clinical and neuroimaging perspectives
Mov Disord
Feb 01, 2026
41 (2) :489-499
Hemicker G, Schwarzová K, Labrecque S, Cerejo C, Carbone F, Peball M, Wimmer B, Mahlknecht P, Krismer F, Djamshidian A, Seppi K, Heim B
Bridging the gap: sex-specific differences in Huntington's disease
Orphanet J Rare Dis
Jan 10, 2026
21 (1) :46
Lee SH, Richardson BD, Ma Y, Marder KS, Garcia TP
SPARCC: Semi-Parametric Robust Estimation in a Right-Censored Covariate Model
J Am Stat Assoc
Jan 02, 2026
Witkowski G, Zielonka D, Rola R, Sienkiewicz-Jarosz H
The association between smoking and Huntington's disease symptom onset and progression - results from Enroll-HD: The observational cohort study of people with Huntington's disease
Neurol Neurochir Pol
Jan 01, 2026
60 (1) :83-91
Knights H, Coleman A, Farag M, Leocadi M, Murphy M, Fayer K, Thackeray O, Langbehn D, Hobbs N, Tabrizi SJ, Scahill RI, HD-YAS investigators
Bias in HD-ISS staging introduced by the FreeSurfer cross-sectional stream: Insights from the Huntington's Disease Young Adult Study (HD-YAS)
J Huntingtons Dis
Nov 01, 2025
14 (4) :396-402
Garcia-Forn M, Castany-Pladevall C, Creus-Muncunill J, Golbano A, Escaramís G, Pérez-Pérez J, Balantzategi U, Hernan-Godoy M, Brito V, Kulisevsky J, Martí E, Pérez-Navarro E
Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients
Neurotherapeutics
Oct 01, 2025
22 (6) :e00716
Di Cecca A, Ilardi CR, Della Pia F, Criscuolo C, Della Sala S, Salvatore E
Distortion errors characterise visuo-constructive performance in Huntington's disease
Clin Neuropsychol
Aug 01, 2025
39 (6) :1615-1633
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium
Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects
Nat Genet
Jun 01, 2025
57 (6) :1426-1436
Stimming EF, Claassen DO, Sen GP, Klepitskaya O, Serbin M, Kim H, Hinton SC, Haubenberger D
Longitudinal treatment patterns of chorea in North American patients with Huntington's disease: Data from Enroll-HD
Neurol Ther
Jun 01, 2025
14 (3) :743-756
Boareto M, Yamamoto Y, Long JD, Sampaio C, McColgan P, Diack C, Ducray PS
Modeling disease progression and placebo response in Huntington disease: Insights from Enroll-HD and GENERATION HD1 cohorts
Neurology
May 27, 2025
104 (10) :e213646
Bakels HS, van der Zwaan KF, Van Zwet E, Reijntjes R, Sprenger GP, Knecht TA, Roos RAC, de Bot ST
Comparison of the clinical spectrum of juvenile- and adult-onset Huntington disease: A national cohort and Enroll-HD observational study
Neurology
May 27, 2025
104 (10) :e213525
Geva M, Goldberg YP, Schuring H, Tan AM, Long JD, Hayden MR
Antidopaminergic medications and clinical changes in measures of Huntington's disease: A causal analysis
Mov Disord
May 01, 2025
40 (5) :928-937
Halabi N, Killoran A, Nopoulos PC, Schultz JL
Differentiating hyperkinetic and hypokinetic motor features in the progression of Huntington's disease
MedRxiv [Preprint]
Apr 21, 2025
Gil-Salcedo A, Lunven M, Jacquemot C, Massart R, Bachoud-Levi AC
Specific contribution of cognitive and motor impairments with functional capacity and dependence in Huntington's disease
J Neurol
Feb 22, 2025
272 (3) :224
Khetarpal V, Herbst T, Dominguez C, Munoz-Sanjuan I, Sampaio C, Marks B, Miller D, Farnham J, Ledvina A, Anglehart H, Rehmani I, LaFayette A, Spridco N, Langbehn D, Wild EJ, Pacifici R
Lack of evidence for kynurenine pathway dysfunction in Huntington’s disease: Cerebrospinal fluid and plasma analyses from the HDClarity study
J Huntingtons Dis
Feb 01, 2025
14 (1) :85-92
van der Zwaan KF, Feleus S, Dekkers OM, Roos RAC, de Bot ST
Total functioning capacity scale in Huntington's disease: natural course over time
J Neurol
Jan 15, 2025
272 (2) :140
Feleus S, Vo MTD, Kuijper LCM, Roos RAC, de Bot ST
Cognitive impairment predicts medication discrepancies in Huntington's disease: patient self-report compared to pharmacy records
J Neurol
Jan 02, 2025
272 (1) :55
Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC
β-blocker use and delayed onset and progression of Huntington disease
JAMA Neurol
Jan 01, 2025
82 (1) :85-92
Feleus S, Skotnicki LEM, Roos RAC, de Bot ST
Medication use and treatment indications in Huntington's disease; analyses from a large cohort
Mov Disord Clin Pract
Dec 19, 2024
11 (12) :1530-1541
Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, Bentivoglio AR
Neuroleptic malignant syndrome in Huntington disease
Eur J Neurol
Dec 01, 2024
31 (12) :e16442
Pollard A, Greetham D, Myatt J, Rickards H, Stanley C, Dungate D
Data-driven Huntington's disease progression modelling and estimation of societal cost in the UK
R Soc Open Sci
Nov 20, 2024
11 (11) :240824
Yao J, Feng B S G, Shao M S G, Mendizabal A, Telesca D, Fang K, Ibragimova L, Shoaib J, Morrison MA, Lupo JM
Interplay between sex and disease burden in Huntington's disease: Clinical and neuroimaging perspectives
MedRxiv [Preprint]
Nov 02, 2024
Gray SM, Dai J, Smith AC, Beckley JT, Rahmati N, Lewis MC, Quirk MC
Changes in 24(S)-hydroxycholesterol are associated with cognitive performance in early Huntington's disease: Data from the TRACK and ENROLL HD cohorts
J Huntingtons Dis
Nov 01, 2024
13 (4) :449-465
Mendizabal A, Ogilvie AC, Bordelon Y, Perlman SL, Brown A
Racial disparities in time to Huntington disease diagnosis in North America: An Enroll-HD analysis
Neurol Clin Pract
Oct 01, 2024
14 (5) :e200344
Mills JA, Long JD, Vaidya JG, Gantman EC, Sathe S, Tabrizi SJ, Sampaio C
Time to functional loss as an endpoint in Huntington's disease trials: Enrichment and sample size
Mov Disord
Oct 01, 2024
39 (10) :1809-1816
Guzauskas GF, Tabrizi SJ, Long JD, Arnesen A, Hamilton JL, Claassen DO, Munetsi LR, Malik S, Rodríguez-Santana I, Ali TM, Zhang F
Long-term health outcomes of Huntington disease and the impact of future disease-modifying treatments: A decision-modeling analysis
Neurol Clin Pract
Oct 01, 2024
14 (5) :e200340